ReviewFrontiers in surgery2025
Liver transplantation for the treatment of neuroendocrine liver metastases.
Review in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine liver metastases (NELM) are commonly observed in patients with advanced neuroendocrine tumors (NETs) and are associated with poor prognosis, primarily due to liver failure and hormone-related complications. While hepatic resection remains the standard surgical approach, orthotopic liver transplantation (OLT) has emerged as a potentially curative treatment in selected patients with unresectable disease. This review summarizes current evidence on the role of OLT in managing NELM, with a focus on patient selection criteria and existing clinical guidelines. Appropriate selection is essential, as improved long-term survival has been consistently demonstrated in patients who meet established eligibility parameters. In conclusion, OLT offers meaningful survival benefits for carefully selected patients with NELM. A multidisciplinary approach and ongoing research into prognostic markers and adjunctive therapies are critical to optimizing outcomes in this challenging clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.